Through the Molecular Pathology Starter Programme, the NIHR BRC is training new scientists in the latest diagnostic techniques

Blood tests known as ‘liquid biopsies’ could represent a major step forward in our ability to detect and monitor breast and other cancers

Professor of Translational Imaging at the ICR

A new approach to clinical trials can help us get novel drugs to patients faster, says Professor Christina Yap, Team Leader in the ICR’s Clinical Trials and Statistics Unit

Consultant Molecular Pathologist at The Royal Marsden

The Lead Research Therapeutic Radiographer at The Royal Marsden and Team Leader in Translational Therapeutic Radiography at the ICR explains how the pioneering MR Linac is being used to treat patients as part of research into its capabilities

There are more than 200 types of cancer that can be classed as uncommon – and experts at The Royal Marsden and the ICR are at the forefront of research into these diseases

The Professor of Oncogenetics at The Institute of Cancer Research, London (ICR) and Consultant in Clinical Oncology and Oncogenetics at The Royal Marsden explains how a genetic test could spot men at risk of developing prostate cancer. 

The Royal Marsden has been approved by NHS England to deliver a new type of immunotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma.

The Institute of Cancer Research, London (ICR) and The Royal Marsden are pioneers in developing new radiotherapy techniques. Recently, we have made great strides in enhancing the imaging of tumours to deliver more targeted radiation. We look at three strands of research that aim to provide more accurate and kinder treatments for patients.